INT325254

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 19
Total Number 19
Disease Relevance 6.56
Pain Relevance 2.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il33) extracellular region (Il33) nucleus (Il33)
Anatomy Link Frequency
mast cell 5
skin 4
bone marrow 1
cleavage 1
band 1
Il33 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 575 99.98 Very High Very High Very High
Inflammatory response 90 97.80 Very High Very High Very High
cytokine 320 94.88 High High
Inflammatory stimuli 19 93.44 High High
Antinociceptive 2 65.76 Quite High
reflex sympathetic dystrophy 3 35.76 Quite Low
chemokine 22 9.20 Low Low
antagonist 21 5.00 Very Low Very Low Very Low
Pain 20 5.00 Very Low Very Low Very Low
Inflammatory mediators 19 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 685 99.98 Very High Very High Very High
Anaphylaxis 396 99.68 Very High Very High Very High
Sprains And Strains 54 98.92 Very High Very High Very High
Pressure And Volume Under Development 59 88.28 High High
Disease 91 80.20 Quite High
Increased Venous Pressure Under Development 36 79.12 Quite High
Asthma 36 77.08 Quite High
Rhinitis 18 65.76 Quite High
Anaemia 18 64.92 Quite High
Necrosis 22 53.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We show that expression of IL-33 in response to IgE-activation required calcium and that ionomycin was sufficient to induce IL-33.
Positive_regulation (induce) of IL-33
1) Confidence 0.69 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2914748 Disease Relevance 0.78 Pain Relevance 0.32
Interestingly, we have observed differences in the baseline levels of IL-33 within the skin of the different strains of mice studied and yet the changes in the levels of IL-33 induced during anaphylaxis were relatively similar.
Positive_regulation (induced) of IL-33 in skin associated with anaphylaxis and sprains and strains
2) Confidence 0.69 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.81 Pain Relevance 0.14
Our data clearly demonstrates that mast cells express IL-33 both in vivo and in vitro and that IL-33 is upregulated upon activation, indicating that mast cells may be an important source of IL-33 during inflammation, likely via its roles as a cytokine.
Positive_regulation (upregulated) of IL-33 in mast cells associated with inflammation and cytokine
3) Confidence 0.69 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.53 Pain Relevance 0.31
Quantification of three independent experiments demonstrated a significant increase in the relative band intensity of the IL-33 protein (858±121 in unstimulated cells to 1393±250 in stimulated cells).
Positive_regulation (increase) of IL-33 protein in band
4) Confidence 0.69 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0 Pain Relevance 0.03
Functionally, we show that IL-33 is expressed within the skin and is upregulated during IgE-driven anaphylaxis.
Positive_regulation (upregulated) of IL-33 in skin associated with anaphylaxis
5) Confidence 0.69 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.54 Pain Relevance 0.12
Utilizing DNP-specific IgE primed BMMC, we show that IL-33 mRNA was upregulated within 30 minutes of stimulation and peaked at 4 hours after antigen-driven activation with DNP-HSA (Figure 1A).
Positive_regulation (upregulated) of IL-33 mRNA
6) Confidence 0.69 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.16 Pain Relevance 0.04
This might suggest strain-specific influences on homeostatic IL-33 levels in cells such as endothelium that do not impact mast cell-derived IL-33.
Positive_regulation (derived) of IL-33 in mast cell associated with sprains and strains
7) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.81 Pain Relevance 0.15
IgE/antigen activation of bone marrow-derived mast cells or a murine mast cell line (MC/9) significantly enhanced IL-33.
Positive_regulation (enhanced) of IL-33 in bone marrow
8) Confidence 0.50 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2914748 Disease Relevance 0.72 Pain Relevance 0.31
Mast cells express IL-33 constitutively and upon activation in vivo
Positive_regulation (upon) of IL-33 in Mast cells
9) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.14 Pain Relevance 0
As shown in Figure 2D, ionomycin-induced IL-33 could be suppressed by addition of EDTA (5 mM) into the culture media.
Positive_regulation (induced) of IL-33
10) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0 Pain Relevance 0.03
To investigate the functional effects of mast cell-derived IL-33, we utilized neutralizing antibodies against ST2 or IL-33 and ST2?
Positive_regulation (derived) of IL-33 in mast cell
11) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.33 Pain Relevance 0.05
Intriguingly, a study recently showed that IL-33 is markedly elevated in patients during anaphylactic shock, suggesting IL-33 may also play a potential role in IgE-mediated reactions in humans also [19].
Positive_regulation (elevated) of IL-33 associated with anaphylaxis
12) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.41 Pain Relevance 0.08
Figure 4C shows that IL-33 levels were significantly elevated at IgE-primed skin sites versus the sham (PBS) injected skin of the same mouse.
Positive_regulation (elevated) of IL-33 in skin
13) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.21 Pain Relevance 0.03
Conversely, IL-33 activation did not alter ST2 expression.
Positive_regulation (activation) of IL-33
14) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0 Pain Relevance 0
To test if IL-33 was upregulated by IgE-driven activation, we investigated IL-33 levels in the skin using a passive cutaneous anaphylaxis model, whereby local mast cell activation is driven by passive IgE priming, followed by systemic antigen challenge.
Positive_regulation (upregulated) of IL-33 in mast cell associated with anaphylaxis
15) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.18 Pain Relevance 0
Low levels of IL-33 protein were detected in unstimulated cells at a full-length size of 31 kD and IgE-mediated stimulation upregulated this form, with no evidence of cleavage products (Figure 1D).
Neg (no) Positive_regulation (upregulated) of IL-33 protein in cleavage
16) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0 Pain Relevance 0.04
IL-33 levels in the skin were significantly elevated only during the late phase.


Positive_regulation (elevated) of IL-33 in skin
17) Confidence 0.46 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2914748 Disease Relevance 0.43 Pain Relevance 0.19
Expression of mRNA for murine IL-4, IL-5, IL-6, IL-33 and ST2 were determined using commercially available FAM-labeled Taqman primers and probes (Applied Biosystems) on cDNA derived from mRNA extracted using a Qiagen RNeasy mRNA isolation kit.
Positive_regulation (murine) of IL-33
18) Confidence 0.22 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.14 Pain Relevance 0
Recently, it was suggested that caspase-1 also metabolises another inflammatory mediator, IL-33; however, contrary to IL-1?
Positive_regulation (mediator) of IL-33 associated with inflammation
19) Confidence 0.20 Published 2010 Journal Mol Pain Section Body Doc Link PMC2959021 Disease Relevance 0.35 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox